-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Reiterates Overweight on Tenax Therapeutics, Maintains $35 Price Target

Benzinga·06/24/2026 14:05:15
Listen to the news
Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates Tenax Therapeutics (NASDAQ:TENX) with a Overweight and maintains $35 price target.